Systemic local-anaesthetic-type drugs in chronic pain: A systematic review

European Journal of Pain

Volumn 2, Issue 1, 1998, Pages 3-14

  Kalso, E ^a,b   Tramer M R ^a,c   McQuay, H J ^a   Moore, R A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; LOCAL ANESTHETIC AGENT; MEXILETINE; TOCAINIDE;

ANALGESIA; CHRONIC PAIN; CLINICAL EXAMINATION; DRUG RESEARCH; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOCAL ANESTHESIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0031837602     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3801(98)90041-6     Document Type: Review

References (40)

1. Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990; 19: 1079-1082.
2. Biella G, Sotgiu ML. Central effects of systemic lidocaine mediated by glycine spinal receptors: an iontophoretic study in the rat spinal cord. Brain Res 1993; 603: 201-206.
3. Bruera E, Ripamonti C, Brennis C, Macmillan K, Hanson J. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992; 7: 138-141.
4. Burchiel KJ. Effects of electrical and mechanical stimulation on two foci of spontaneous activity which develop in primary afferent neurons after peripheral axotomy. Pain 1984; 18: 249-265.
5. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989; 38: 333-338.
6. Chabal C, Jacobson L, Mariano A, Chaney E, Britel C. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992; 77: 513-517.
7. Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil 1996; 75: 84-87.
8. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; I: 9-11.
9. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992; 48: 261-268.
10. Dunlop R, Davies RJ, Hockley J, Turner P. Letter to the Editor. Lancet 1989; I: 420-421.
11. Ellemann K, Sjögren P, Banning A-M, Jensen TS, Smith T, Geertsen P. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 1989; 5: 291-294.
12. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent reponse to oral mexiletine: a prospective study. J Pain Symptom Manage 1996; 12: 161-167.
13. Gertz MA, Garton JP, Jennings WH. Aplastic anemia due to tocainide. N Engl J Med 1986; 314: 583-584.
14. Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial. I. report on arrhythmia and other findings. J Am Coll Cardiol 1984; 4: 1148-1163.
15. Jacox A, Carr DB, Payne R. Management of Cancer Pain. Clinical Practice Guideline No. 9 Agency for Health Care Policy and Research Udo. AHCPR Publication No. 94-0592. Rockville, M.D: Public Health Service 1994: 41-74.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17: 1-12.
17. Kastrup J, Angelo H, Petersen P, Dejgård A, Hilsted J. Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J 1986; 292: 173.
18. Kastrup J, Petersen P, Dejgård A, Angelo HR, Hilsted J. Intravenous lidocaine infusin - a new treatment of chronic painful diabetic neuropathy? Pain 1987; 28: 69-75.
19. Keats AA, D'Alessandro GL, Beecher HK. A controlled study of pain relief by intravénous procaine. JAMA 1951; 147: 1761-1763.
20. Kugelberg E, Lindblom U. The mechanism of the pain in trigeminal neuralgia. J Neurol Neurosurg Psychiat 1959; 22: 36-43.
21. L'Abbé LA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224-233.
22. Lindström P, Lindblom U. The analgesic effect of tocainide in trigeminal neurlgia. Pain 1987; 28: 45-50.
23. Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine. JAMA 1996; 276: 319-321.
24. Marbach JJ, Wallenstein SL. Analgesic, mood, and hemodynamic effects of intranasal cocaine and lidocaine in chronic facial pain of deafferentation and myofascial origin. J Pain Symptom Manage 1988; 3: 73-79.
25. Perlow GM, Jain BP, Pauker SG, Zarren HS, Wistran DC, Epstein RL. Tocainide-associated interstitial pneumonitis. Ann Intern Med 1981; 94: 489-490.
26. Petersen P, Kastrup J, Zeeberg I. Intravenoøs lidokain i behandling af kroniske smerter. Ugeskr Læger 1986a; 148: 2158-2159.
27. Petersen P, Kastrup J, Zeeberg I, Boysen G. Chronic pain treatment with intravenous lidocaine. Neurol Res 1986b; 8: 189-190.
28. Reutens DC, Fatovich DM, Stewart-Wynne EG, Prentice DA. Is intravenous lidocaine clinically effective in acute migraine? Cephalalgia 1991; 11: 245-247.
29. Roden DM. Tocainide and mexiletine - orally effective lidocaine analogues. Arch Intern Med 1985; 145: 417-418.
30. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of post-herpetic neuralgia. Neurology 1991; 41: 1024-1028.
31. Scadding JW. Development of ongoing activity, mechanosensitivity, and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol 1981; 73: 345-364.
32. Sjøgren P, Banning A-M, Hebsgaard K, Petersen P, Gefke K. Intravenøs lidokain i behandling af kroniske smerter forrsaget af knoglemetastaser. Ugeskr Læger. 1989; 151: 2144-2146.
33. Soff GA, Kadin ME. Tocainide-induced reversible agranulocytosis and anemia. Arch Intern Med 1987; 147: 598-599.
34. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992; 15: 1550-1555.
35. Stracke H, Meyer U, Schumacher H, Armbrecht U, Beroniade S, Buch K-D, Federlin K, Haupt E, Husstedt IW, Kampmann B, Richter W, Sonnichsen A, Zenker H. Mexiletine in der Behandlung der schmerzhaften diabetischen Neuropathie. Med Klin 1994; 89: 124-131.
36. Sörensen J, Bengtsson A, Bäckman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Scand J Rheumatol 1995; 24: 360-365.
37. Tanelian DL, Maclver MB. Analgesic concentrations of lidocaine suppress tonic A-delta and C-fiber discharges produced by acute injury. Anesthesiology 1991; 74: 934-936.
38. Wall PD, Gutnick M. Properties of afferent nerve impulses originating from a neuroma. Nature (London) 1974; 248: 740-743.
39. Wall PD, Devor M. Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats. Pain 1983; 17: 321-339.
40. Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for evaluation of neuropathic pain after peripheral nerve injury. Pain 1996; 66: 69-77.